Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atreleuton

Next Previous
Drug Profile

Atreleuton

Alternative Names: A 85761; ABT 761; VIA 2291

Latest Information Update: 08 Feb 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer VIA Pharmaceuticals
  • Class Anti-inflammatories; Cardiovascular therapies; Small molecules; Urea compounds
  • Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute coronary syndromes; Asthma; Atherosclerosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 20 May 2010 Updated pharmacodynamics data from a substudy of a Phase-II trial in Acute coronary syndromes released by VIA Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top